The CRC Blueprint

My scientific approach to my own cancer – shared with you.

Phase 2

Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease

Phase 2 · randomised · 90 people · 14 sites in 8 countries · Recruiting now

August 8, 2026
Dual-Targeting CAR-NK Cells in Biomarker-Selected Advanced Colorectal Cancer

Phase 2 · 48 people · 1 site in China · Recruiting now

August 8, 2026
Low-Dose Radiotherapy to Sensitize Pucotenlimab Plus CAPEOX for pMMR Locally Advanced Rectal Cancer

Phase 2 · randomised · 50 people · 1 site in China · Recruiting now

August 8, 2026
TL938 and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer

Phase 2 · randomised · 80 people · 1 site in China · Recruiting now

August 8, 2026
AK104 Plus Radiotherapy Combined With Standard Therapy Versus Standard Therapy as First-Line Treatment for pMMR/MSS CRLM

Phase 2 · randomised · 73 people · 1 site in China · Recruiting now

August 8, 2026
Phase II Study of EMB-01 in Recurrent/Metastatic Colorectal Cancer Patients

Phase 2 · randomised · 54 people · 2 sites in China · Recruiting now

August 8, 2026
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

Phase 2 · 534 people · 55 sites in 7 countries · Recruiting now

August 8, 2026
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

Phase 2 · 542 people · 82 sites in 4 countries · Recruiting now

August 8, 2026
Tislelizumab in People With Colorectal Cancer

Phase 2 · 40 people · 3 sites in 2 countries · Recruiting now

August 8, 2026
FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer

Phase 2 · randomised · 60 people · 15 sites in United States · Recruiting now

August 8, 2026